PartnershipAug 13, 2026, 07:31 AM
Cerenome's CNSide Expands Access to 153M Lives via HCSC Deal
AI Summary
CNSide Diagnostics, a wholly-owned subsidiary of Cerenome, Inc., announced an in-network provider agreement with Health Care Service Corporation (HCSC). This partnership adds approximately 27.3 million covered lives, bringing CNSide's total contracted access to 153 million commercial and Medicare Advantage covered lives. This achievement surpasses the company's 2026 full-year objective of 150 million covered lives ahead of schedule, aiming to expand patient access and drive physician adoption of the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay.
Key Highlights
- CNSide Diagnostics signed an in-network provider agreement with HCSC.
- HCSC represents approximately 27.3 million commercial and Medicare Advantage covered lives.
- CNSide now has contracted access to approximately 153 million covered lives.
- This exceeds the 2026 full-year objective of 150 million covered lives.
- The agreement became effective on August 1, 2026.
- More than 11,000 CNSide® tests have been performed since 2020.
- Tests have been performed at over 120 U.S. cancer institutions.
Price Impact
More from PSTV